Literature DB >> 16141666

Macrolides and lincomycin susceptibility of Mycoplasma hyorhinis and variable mutation of domain II and V in 23S ribosomal RNA.

Hideki Kobayashi1, Hiromi Nakajima, Yuka Shimizu, Masashi Eguchi, Eiji Hata, Koshi Yamamoto.   

Abstract

A total of 151 strains of Mycoplasma hyorhinis isolated from porcine lung lesions (weaned pigs, n=71, and finishers, n=80) were investigated for their in vitro susceptibility to 10 antimicrobial agents. Thirty-one strains (28 from weaned pigs and 3 from finishers) showed resistance to 16-membered macrolide antibiotics and lincomycin. The prevalence of the 16-membered macrolide-resistant M. hyorhinis strain in weaned pigs from Japanese herds has approximately quadrupled in the past 10 years. Several of the 31 strains were examined for mutations in the 23S ribosomal RNA (rRNA). All field strains tested showed a transition of A to G at position 2059 of 23S rRNA-rendered Escherichia coli. On the other hand, individual tylosin- and lincomycin-resistant mutants of M. hyorhinis were selected in vitro from the susceptible type strain BTS7 by 3 to 9 serial passages in subinhibitory concentrations of each antibiotic. The 23S rRNA sequences of both tylosin and lincomycin-resistant mutants were compared with that of the radical BTS7 strain. The BTS7 mutant strain selected by tylosin showed the same transition as the field-isolated strains of A2059G. However, the transition selected in lincomycin showed mutations in domains II and V of 23S rRNA, G2597U, C2611U in domain V, and the addition of an adenine at the pentameric adenine loop in domain II. The strain selected by lincomycin showed an additional point mutation of A2062G selected by tylosin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141666     DOI: 10.1292/jvms.67.795

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  6 in total

1.  Mutations Associated with Decreased Susceptibility to Seven Antimicrobial Families in Field and Laboratory-Derived Mycoplasma bovis Strains.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Enikő Wehmann; Inna Lysnyansky; Krisztián Bányai; Szilvia Marton; Ákos Jerzsele; Zsuzsanna Rónai; Ibolya Turcsányi; László Makrai; Szilárd Jánosi; Sára Ágnes Nagy; Miklós Gyuranecz
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Relationship between Antimicrobial Susceptibility and Multilocus Sequence Type of Mycoplasma bovis Isolates and Development of a Method for Rapid Detection of Point Mutations Involved in Decreased Susceptibility to Macrolides, Lincosamides, Tetracyclines, and Spectinomycin.

Authors:  Eiji Hata; Takehiro Harada; Megumi Itoh
Journal:  Appl Environ Microbiol       Date:  2019-06-17       Impact factor: 4.792

3.  Characterization of in vivo-acquired resistance to macrolides of Mycoplasma gallisepticum strains isolated from poultry.

Authors:  Irena Gerchman; Sharon Levisohn; Inna Mikula; Lucía Manso-Silván; Inna Lysnyansky
Journal:  Vet Res       Date:  2011-08-02       Impact factor: 3.683

4.  Antimicrobial susceptibility profiles of porcine mycoplasmas isolated from samples collected in southern Europe.

Authors:  Rubén S Rosales; Ana S Ramírez; María M Tavío; Carlos Poveda; José B Poveda
Journal:  BMC Vet Res       Date:  2020-09-03       Impact factor: 2.741

5.  Antimicrobial susceptibility profiles of Mycoplasma hyorhinis strains isolated from five European countries between 2019 and 2021.

Authors:  Ulrich Klein; Dorottya Földi; Nikolett Belecz; Veronika Hrivnák; Zoltán Somogyi; Michele Gastaldelli; Marianna Merenda; Salvatore Catania; Arkadiusz Dors; Ute Siesenop; Philip Vyt; Zsuzsa Kreizinger; Wouter Depondt; Miklós Gyuranecz
Journal:  PLoS One       Date:  2022-08-11       Impact factor: 3.752

6.  Decontamination of mycoplasma-contaminated Orientia tsutsugamushi strains by repeating passages through cell cultures with antibiotics.

Authors:  Motohiko Ogawa; Tsuneo Uchiyama; Masaaki Satoh; Shuji Ando
Journal:  BMC Microbiol       Date:  2013-02-08       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.